Stay updated on Avutometinib and Defactinib in Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.

Latest updates to the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous Revision: v3.6.2. This indicates a minor system update.SummaryDifference0.0%

- Check11 days agoChange DetectedAn updated study overview was added, detailing the evaluation of avutometinib and defactinib for RAF dimer-driven thyroid cancers and the safety profile. The FDA OOPD funding line was added, and the previous version of the description and its revision notes was removed.SummaryDifference0.3%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedNew quick links were added to the Study Details page (Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, How to Join a Study), and the label for Intervention/Treatment was adjusted. The version tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check33 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5. This reflects a minor update to the published page without altering the study content.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page's revision line changed from v3.5.3 to v3.5.4, indicating a new release of the page content. This update reflects a metadata or maintenance release rather than a substantive change to the page's information.SummaryDifference0.1%

- Check75 days agoChange DetectedThis update refreshes the website’s version/revision footer from v3.5.2 to v3.5.3 without changing the study record content.SummaryDifference0.1%

Stay in the know with updates to Avutometinib and Defactinib in Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.